Home » COLLAGENEX PHARMACEUTICALS SUBMITS ADDITIONAL INFORMATION TO USPTO
COLLAGENEX PHARMACEUTICALS SUBMITS ADDITIONAL INFORMATION TO USPTO
CollaGenex Pharmaceuticals, Inc. today announced that it has submitted additional information to the U.S. Patent and Trademark Office (USPTO) that may be relevant to the examination of U.S. Patent Application, Serial No. 10/117,709. This application relates to the use of sub-antimicrobial and non-antimicrobial tetracyclines for the treatment of acne and acne rosacea, including Oracea(TM) and incyclinide.
Genetic Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May